DeoBioSciences, with a post-money valuation of $16.67 million, is testing the waters on NetCapital. The company is developing treatment against metastatic cancer in pets and people. The cancer drug will be based on a naturally-occurring compound that can kill both early and advanced-stage cancer cells. John F. Adamson founded DeoBioSciences in 2000. The proceeds of the current crowdfunding campaign, with a minimum raise of $10,000 and a maximum raise of $1,070,000, will be used for pre-clinical drug manufacturing, pre-clinical animal trials, payroll and benefits, R&D consultants, and other miscellaneous expenses. DeoBioSciences has received letters of interest from major biotech companies for in-licensing and partnerships.